Alps Advisors Inc Zai Lab LTD Transaction History

Alps Advisors Inc

$17.2 Billion
Q1 2025

A detailed history of Alps Advisors Inc transactions in Zai Lab LTD stock. As of the latest transaction made, Alps Advisors Inc holds 76,298 shares of ZLAB stock, worth $2.42 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

76,298

Previous 88,395 13.69%

Holding current value

$2.42 Million

Previous $2.32 Million 19.09%

% of portfolio

0.02%

Previous 0.01%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 Apr 30, 2025	SELL	$24.29 - $38.35 $293,836 - $463,919	-12,097 Reduced 13.69%	76,298 $2.76 Million
Q4 2024 Feb 13, 2025	BUY	$24.61 - $33.18 $337,895 - $455,561	13,730 Added 18.39%	88,395 $2.32 Million
Q3 2024 Nov 12, 2024	SELL	$16.25 - $24.14 $80,876 - $120,144	-4,977 Reduced 6.25%	74,665 $1.8 Million
Q2 2024 Aug 13, 2024	BUY	$13.72 - $21.55 $135,100 - $212,202	9,847 Added 14.11%	79,642 $1.38 Million
Q1 2024 May 14, 2024	BUY	$15.95 - $26.8 $46,845 - $78,711	2,937 Added 4.39%	69,795 $1.12 Million
Q4 2023 Feb 14, 2024	SELL	$22.97 - $30.58 $137,452 - $182,990	-5,984 Reduced 8.22%	66,858 $1.83 Million
Q3 2023 Nov 14, 2023	BUY	$22.72 - $31.49 $51,415 - $71,261	2,263 Added 3.21%	72,842 $1.77 Million
Q2 2023 Aug 14, 2023	BUY	$25.3 - $39.67 $51,080 - $80,093	2,019 Added 2.94%	70,579 $1.96 Million
Q1 2023 May 10, 2023	BUY	$30.21 - $48.1 $64,709 - $103,030	2,142 Added 3.23%	68,560 $2.28 Million
Q4 2022 Feb 14, 2023	BUY	$22.28 - $38.71 $223,869 - $388,958	10,048 Added 17.83%	66,418 $2.04 Million
Q3 2022 Nov 14, 2022	SELL	$34.2 - $51.69 $58,482 - $88,389	-1,710 Reduced 2.94%	56,370 $1.93 Million
Q2 2022 Aug 11, 2022	BUY	$23.14 - $49.68 $1.34 Million - $2.89 Million	58,080 New	58,080 $2.01 Million

Others Institutions Holding ZLAB

# of Institutions

156

Shares Held

49.8M

Call Options Held

103K

Put Options Held

439K

View Full List

About Zai Lab Ltd

Ticker ZLAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,908,704
Market Cap $3.1B
Description
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...

More about ZLAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Alps Advisors Inc with notifications on news.

Account

Alps Advisors Inc Zai Lab LTD Transaction History